The trk locus was first identified as a transforming gene in a human colon carcinoma biopsy (1) (2) (3) . This locus encodes a cell surface receptor of the tyrosine kinase family (4) . The TrkA gene product is a prototype for a subfamily of tyrosine kinase receptors including TrkB and TrkC (5-7). The Trk family of tyrosine kinases acts as functional receptors for the neurotrophins: nerve growth factor, brain-derived neurotrophic factor (BDNF), 1 neurotrophin-3 (NT-3), NT-4/5, and probably NT-6 (7-11).
Although the overall sequence homology between the extracellular domains of the Trk receptors is approximately 60%, each receptor specifically binds a subset of the neurotrophins. Recently, two distinct domains in the Trk receptors have been reported to contain neurotrophin binding sites. One region is the LRM domain of the TRK receptor as determined from expression of an unfolded fusion protein encoding the LRM region in Escherichia coli (12, 13) . Analysis of a series of extracellular deletions and TRK chimeras indicated that the second Ig-like region was important for both neurotrophin binding and receptor activation (14, 15) . In particular, these studies showed that the second Ig-like domain confers specificity and provides the main contacts for binding to Trk receptors by their ligands.
Concurrently, receptor binding sites in the neurotrophins have been investigated by site-directed mutagenesis (for review, see Ref. 16 ). Although loop V (residues 94 -98) of the neurotrophins is commonly thought to be the receptor binding region, extensive site-directed mutagenesis studies on NT-3 indicated that amino acid residue Arg 103 affected biological activity significantly (17, 18) . In another study, small monomeric cyclic peptide analogs that mimic the ␤-turn regions of nerve growth factor were synthesized, and one region (amino acid residues 92-96) exhibited competitive inhibition and affected the biological response of treated cells (19) . Recently, in the erythropoietin-erythropoietin receptor system, small Cyscontaining peptides consisting of 20 amino acids were shown to dimerize the receptor (20) . In total, these reports encouraged us to study the binding properties of small peptide fragments of TRKB to BDNF to identify critical amino acid residues.
A variety of chemical approaches has been used to investigate receptor-ligand interactions or protein-protein interactions with immobilized ligand on membrane filters or agarose beads (21) (22) (23) (24) (25) . MALDI-mass spectrometry in combination with proteolytic protection assays has been used to identify functional epitopes (24) . The affinity-based approach has been used for chemical libraries prepared on beads or pins but has rarely been used in screening a library in solution or natural product extracts. One example of such an approach was the determination of which interleukin-6 peptide fragments interacted with its receptor using dot analysis on immobilized ligandbound membrane (21) . However, this approach was useful only when the primary structure alone contributed to most of the receptor-ligand interactions. Moreover, nonspecific binding of some particular peptides on agarose or Sepharose beads can occur, thus complicating analysis. Therefore, it is desirable to study the binding properties of protein or peptide fragments under more native conditions. In this paper, we report the isolation of BDNF binding regions of TRKB under mild conditions, using affinity separation on immobilized BDNF and comparison of binding with synthetic peptide analogs.
EXPERIMENTAL PROCEDURES
Materials-Trypsin, endoproteinases Asp-N, Glu-C, and Lys-C were obtained from Boehringer Mannheim. Aminopropyl glass beads (75 or 170 Å pore size, 200 -400 mesh) were obtained from Sigma. EDAC and bissulfosuccinimidyl suberate were purchased from Pierce Chemical Co. N-Glycanase was obtained from Genzyme. Recombinant human metBDNF was expressed in E. coli and was purified at Amgen Inc. All other chemicals were HPLC grade.
Purification of an Extracellular Domain and the Truncated Form of TRKB-The DNA construct for the extracellular domain of human TRKB encoded a 429-amino acid polypeptide containing the signal sequence and the extracellular domain of the human TRKB receptor (residues 1-398) (5) . When this construct was expressed in Chinese hamster ovary cells as described previously (26, 27) , the signal sequence was cleaved to produce the soluble TRKB protein (residues 1-398) containing carbohydrate moieties. The protein was purified by a singlestep affinity method from transfected Chinese hamster ovary cell-conditioned medium. According to laser desorption-mass spectrometry, the resulting glycoprotein had a molecular mass of approximately 61 kDa as described previously (26) . A truncated TRKB encoding a COOHterminal Ig-like domain (residues 247-398) was expressed in E. coli cells. The cell paste was resuspended in 10 mM sodium phosphate buffer, pH 7.4, containing 0.15 M NaCl, 10 mM EDTA, and 10 mM dithiothreitol and was disrupted using a microfluidizer. The TRKB inclusion bodies were pelleted by centrifugation and washed with the above buffer containing 1% deoxycholate. The inclusion bodies were solubilized in 1 N lauroyl sarcosine and 6 M GdnHCl and then refolded in Tris-HCl buffer, pH 8.3, containing oxidized and reduced glutathione at a 1:1 ratio. The correctly refolded protein was bound to a BDNFSepharose column and eluted with 0.5 M NaCl-sodium acetate buffer, pH 4.0. The apparent molecular mass of the truncated TRKB was determined by SDS-PAGE (28) .
Preparation of Covalently Attached Protein-Glass Beads-BDNF-immobilized glass beads were prepared using the cross-linker, bissulfosuccinimidyl suberate. Aminopropyl glass beads (75 or 170 Å pore size, approximately 40 mg) (Sigma) were placed in microcentrifuge tubes, suspended in water, and equilibrated in 0.1 M sodium phosphate buffer, pH 7.5. After suspension, the glass beads were washed with 2 ml of the same buffer and centrifuged in a Pico Fuge (Peninsula Laboratory, Belmont, CA). The beads were resuspended in 500 l of the same buffer and reacted with excess bissulfosuccinimidyl suberate (approximately 5 mg) for 5 min at 25°C. The glass beads were immediately washed twice with 1 ml of 0.1 M potassium phosphate buffer, pH 7.5, then the beads were mixed slowly with BDNF solution (100 g/10 l) in 500 l of 0.1 M phosphate buffer, pH 7.5. After 30 min of incubation, the BDNF-attached beads were washed twice with 1 ml of 0.1 M Tris-HCl buffer, pH 7.5, followed by 0.1 M Tris-HCl containing 2 M sodium chloride. Finally, the beads were equilibrated with 0.1 M Tris-HCl buffer, pH 7.5.
Proteolytic Fragmentation of the Soluble TRKB and the Truncated TRKB-The soluble and truncated TRKB proteins (approximately 50 g) were digested with several enzymes including trypsin, endoproteinases Asp-N, Lys-C, or Glu-C in 200 l of 0.1 M Tris-HCl buffer, pH 7.5, at a ratio of 1:50 (w/w) for enzyme to protein. To obtain large fragments, the digestion time varied from 4 to 18 h at 37°C. Suitable digestion conditions were examined by reversed phase HPLC using a Vydac C18 column (2.1 ϫ 150 mm or 4.6 ϫ 250 mm). Deglycosylation of glycopeptides (10 -50 g) was carried out using 0.2 unit of N-glycanase at 37°C in 0.1 M Tris-HCl buffer, pH 7.5. Pepsin digestion of EDAC-coupled protein was carried out at 37°C for 18 h in 0.02 N HCl at a ratio of 1:50 (w/w) for enzyme to protein.
Elution of BDNF Binding Peptides from Immobilized Ligand Beads-Proteolytic digests of the soluble TRKB or the truncated TRKB were mixed with BDNF-bound beads in 0.1 M Tris-HCl buffer, pH 7.5, and incubated at 4°C for 1 h using a laboratory mixer (Barnstead/ Thermolyne). The incubated sample was centrifuged in a microcentrifuge at 14,000 rpm for 5 min, and the supernatant was collected into a tube (W1). The beads were washed with 500 l of 0.1 M Tris-HCl buffer, pH 7.5. After vortex mixing for a few minutes followed by centrifugation as above, the supernatant (W2) was collected. BDNF binding peptides were first eluted with 500 l of 2 M NaCl, 0.1 M Tris-HCl, pH 7.5, by agitation for a few minutes at room temperature followed by centrifugation, and the supernatant (E1) was collected. The elution was followed by incubation with 2 M GdnHCl, 0.75 N HCl (400 l) to remove completely any remaining peptides bound to the BDNF-glass beads (E2).
BDNF Binding Assay of Soluble TRKB and the Truncated TRKB-BDNF binding to the soluble TRKB or the truncated TRKB was measured by passing solutions containing the extracellular portion of TRKB (5 l/min) over biosensor chip surfaces immobilized with BDNF (immobilized through amine groups) as described previously (29, 30) . Binding constants for BDNF and TRKB variants were calculated using a nonlinear fit program in bioevaluation (Biosensor AB) using a 1:1 binding and dissociation model and assuming that no rebinding was taking place (29 -32) . Determinations were run in this orientation to compare binding between TRKB samples more accurately. Sample dilutions were run in triplicate and repeated on different biosensor surfaces.
EDAC Cross-linking Reaction between BDNF and TRKB ReceptorThe truncated form of TRKB (68 g) was mixed with BDNF (75 g) in 100 l of 0.1 M MES buffer, pH 5.0, and cross-linked by treatment with 5 mM EDAC for 60 min at room temperature. The reaction was quenched by the addition of 15 l of 1 M ammonium acetate. Crosslinking products were separated by gel filtration using a Superdex 75 column (10 ϫ 300 mm, Pharmacia Biotech Inc.) equilibrated with 0.45 M sodium chloride, 0.2 M sodium acetate buffer, pH 5.0. The flow rate was 0.30 ml/min. The protein fractions were purified further by reversed phase HPLC using a Zorbax CN column (2.1 ϫ 150 mm). Reversed phase HPLC was performed at room temperature using a linear gradient elution from 0.1% trifluoroacetic acid (solvent A) to 0.1% trifluoroacetic acid, 90% acetonitrile (solvent B). The cross-linked proteins were eluted with a linear gradient from 20% B to 60% B over 30 min with a flow rate of 0.25 ml/min. The protein fractions were analyzed by SDS-PAGE as described previously (28) .
Peptide Separation and Other Analytical Methods-Peptide separation was performed by reversed phase HPLC using a Vydac C18 column (2.1 ϫ 150 mm). The peptides were eluted with a linear gradient using 0.1% trifluoroacetic acid (solvent A) and 0.1% trifluoroacetic acid, 90% acetonitrile (solvent B). Normally, the protein or peptides were first eluted with a linear gradient from 2% B to 40% B over 30 min followed by elution with a second gradient from 40% B to 60% B over 10 min with a flow rate of 0.25 ml/min. The peptides were detected at both 215 nm and 280 nm. For determination of the molecular mass of protein or peptide, ion spray-mass spectrometry (Sciex III API triple quadrupole) or MALDI-mass spectrometry was used (26) . Sequence analysis of the peptides was performed by an Applied Biosystems Inc. gas phase sequencer model 470A or 477A.
RESULTS
Purification of Soluble TRKB and the Truncated TRKB-As an initial step in trying to identify BDNF binding domains, we expressed two recombinant versions of the extracellular domain of the human TRKB receptor. One version corresponds to the entire extracellular domain of the receptor. This recombinant protein contained 398 amino acids, 30% (by weight) carbohydrates, and had a molecular mass of approximately 61 kDa as determined by laser desorption-mass spectrometry (26) . The other recombinant protein was a truncated TRKB receptor and was produced by expressing the second Ig-like domain of soluble TRKB (residues 248 -398) in E. coli cells. This form of TRKB was refolded and contained 152 amino acids including one disulfide bond and a free cysteine (Cys 300 ). Purification of the truncated TRKB was performed by BDNF affinity chromatography as described earlier for the entire extracellular domain (26, 27) . The purified protein migrated as a single band on SDS-PAGE, exhibiting an apparent molecular mass of approximately 23 kDa (Fig. 1) , somewhat higher than the predicted value of 17,200. Peptide analysis revealed that the free cysteine residue (Cys 300 ) was glutathionylated during the expression or purification process.
BDNF Binding of Soluble and the Truncated Forms of TRKB-BDNF binding activity to the TRKB receptor was measured using surface plasmon resonance as described under "Experimental Procedures." The results show that both the soluble and the truncated form of TRKB are capable of binding BDNF. Calculated binding constants (K d ) for the soluble and the truncated forms of TRKB toward BDNF were approximately 9 nM and 43 nM, respectively. The K d of a full-length form of TRKB expressed in a cell line was shown to be approximately 1-1.8 nM (33) . The K d values determined here are slightly higher.
Isolation of BDNF Binding Fragments from Soluble TRKB-To identify regions of the TRKB receptor which bound to BDNF, we developed BDNF-glass beads as an affinity capture reagent. BDNF-attached glass beads were prepared from aminopropyl glass beads after treatment with the cross-linker bissulfosuccinimidyl suberate. The activated glass beads were cross-linked to BDNF as shown in Fig. 2 . Cross-linking efficiency to the glass beads was greater than 80% of starting materials when BDNF (100 g) and glass beads (100 l, wet volume) were used. BDNF-coupled beads were capable of inducing TRKB phosphorylation of the full-length receptor, indicating that the coupled BDNF was biologically active (data not shown). To cleave TRKB into smaller domains, several enzymatic digestions using endoproteinases Lys-C, Glu-C, and Asp-N were performed. However, only a Lys-C digest of soluble TRKB provided useful information for identifying BDNF binding regions. After a 20-h digestion, the enzymatic digest was incubated with BDNF-immobilized glass beads, and the ligandbound and -unbound peptides were separated by washing and elution from the BDNF-glass beads (Fig. 2) . A total of four fractions including a flow-through fraction (named as W1), a wash fraction (W2), and fractions eluted with 2 M NaCl, 0.1 M Tris-HCl) (E1) and 2 M GdnHCl, 0.75 N HCl (E2) were analyzed by reversed phase HPLC (Fig. 3, A-C) . When the Lys-C digest of soluble TRKB was incubated with BDNF-glass beads, peptide peaks AK-1 and AK-2 were significantly depleted from the flow-through fraction because of binding to the BDNF beads (Fig. 3B) . These peptides appeared only after elution with 2 M NaCl, 0.1 M Tris-HCl, pH 7.5 ( Fig. 3C) , suggesting that peaks AK-1 and AK-2 were potential ligand binding peptides. Fraction E2 gave a signal corresponding to peak AK-2 as well as a peak corresponding to BDNF stripped off the glass beads (data not shown). Parallel experiments indicated that the nonspecific binding of the peptides to the glass beads was minimal; namely, peaks AK-1 and AK-2 as well as other peptides had no interaction with unmodified glass beads (data not shown). An endoproteinase Asp-N digest of soluble TRKB was also examined on BDNF binding affinity, but no significant interaction of the peptides with the immobilized BDNF beads was observed. The likely explanation is that the endoproteinase Asp-N-generated peptides were not large enough for ligand binding, or some critical BDNF binding region was cleaved with the enzyme, resulting in loss of BDNF binding affinity.
Analysis of BDNF Binding Peptides AK-1 and AK-2-A comparison of three peptide maps (Fig. 3, A-C) , including the whole digest, a flow-through fraction (W1), and eluted fractions (E1) (Fig. 3, A-C) , shows that peaks AK-1 and AK-2 were able to bind to immobilized BDNF. Sequence analysis of peak AK-1 showed that the first 14 residues were Q-I-S-A-H-F-M-G-W-P-G-I-D-D (Table I) . This Lys-C-generated peptide was glycosylated (26) , and a molecular mass estimate of this peptide as determined by mass spectrometry varied because of carbohydrate heterogeneity. After treatment with N-glycanase, however, the peptide indicated one mass of 5,761 atomic mass units for its expected value of 5,760.1 atomic mass units and was revealed to be derived from a COOH-terminal region of the soluble TRKB, corresponding to Q-
342-394) (data not shown). The second peak AK-2 showed three sequences because of connections through two disulfide linkages (Table II) . This fragment contained a part of the LRM-3 region and the cysteine cluster-2 region (residues 103-181). After deglycosylation with N-glycanase, the peptide peak AK-2 gave a mass of 8,048.5, nearly identical to the expected mass of the three Cys-containing peptides, 8,048.0 atomic mass units.
Isolation of BDNF Binding Peptides after Reduction and Alkylation-To examine the significance of the disulfide bonds of the peptide AK-2 for BDNF binding, the Lys-C digest was further reduced, carboxymethylated, and tested for BDNF binding by affinity separation as described above. Examination of the HPLC peptide maps (Fig. 4) indicated that peak RCMK-1 only appeared after elutions with both 2 M NaCl, 0. 
TABLE II Sequence analysis of BDNF-bound fragment AK-2
Sample amount analyzed was approximately 80 pmol. Only eight cycles were run. After deglycosylation, the atomic mass units observed were 8048.5 the atomic mass units calculated were 8048, which assumed that sequence 1 was derived from residues 103-129, sequence 2 from residues 136 -151, and sequence 3 from residues 152-181. All of these peptides were linked through two disulfide bonds (26 RCMK-1 was identical to that of glycopeptide AK-1. Multiplicity of the peptide peak was caused by the carbohydrate heterogeneity as described above. These peaks only contained one NH 2 -terminal sequence as shown above, and direct mass spectrometry indicated several higher values than the expected mass of 5,760.1 atomic mass units. However, after deglycosylation these peaks gave the same mass of 5,761 atomic mass units. The peak corresponding to peptide AK-2 ( Fig. 3) was not observed in the eluted fractions (E1 and E2), implying that the disulfide bonds of the peptide AK-2 were essential for maintaining BDNF binding affinity.
Isolation of BDNF Binding Peptides from the Truncated TRKB-
The truncated TRKB expressed in E. coli consisted of a region from residues 248 to 398, containing the second Ig-like domain and a COOH-terminal region adjacent to the transmembrane region. It contained three cysteine residues; one disulfide linkage Cys 271 -Cys
314
, and a free cysteine residue (Cys 300 ) consistent with the previous report of disulfide bond formation in the TRKB receptor (26) . The free cysteine was occasionally glutathionylated during the expression/purification processes. Similar to the affinity binding experiments with limited proteolysis of soluble TRKB, BDNF binding peptides from the truncated TRKB were examined on immobilized BDNF beads. Fig. 5 shows the peptide maps from four fractions including washing and elution fractions (W1, W2, E1, and E2) described above. Peptide TFK-1 was depleted significantly after incubation of the digest with immobilized BDNF-glass beads (Fig. 5B ) and detected after elution (E2), indicating a BDNF binding peptide. The sequence of peptide TFK-1 was identical to that of peptides AK-1 or RCMK-1, although the latter peptides contained N-glycosylation. Interestingly, the E. coli expressed protein apparently bound to immobilized BDNF differently because the bound peptide TFK-1 was eluted only with the second elution (E2).
A Comparison of BDNF Binding by Several Synthetic Peptides and Synthetic Analogs-Several samples including
COOH-terminal glycopeptide AK-1, nonglycosylated peptide TFK-1, TRKB truncated form, and soluble TRKB were all able to bind BDNF. To define further the BDNF binding sites, the binding ability of several synthetic peptides corresponding to peptide AK-1 was tested. Some particular amino acid residues of these synthetic peptides AP-1-6 were replaced by Ala (Fig.  6) . Results from binding experiments with these peptides show that the peptides SP (wild-type) and AP-1 have similar binding abilities (Table III) , approximately 60% relative binding according to the calculation method (Table III) , whereas peptides AP-2 and -3 showed slightly lower binding activity (50% relative binding). Under the same conditions used above, the synthetic peptides SP or analogs AP-1-6 did not bind to unmodified glass beads. Synthetic peptides spanning the three LRM regions (LRM-1, LRM-2, and LRM-3) (3) were also made, and the binding properties were examined. The results indicated that only a peptide containing LRM-3 region (residues 90 -120) could partly bind to the immobilized BDNF (relative binding, 37%). This is consistent with the results from affinity purification as described above.
EDAC Coupling between BDNF and Truncated TRKB-After identifying a COOH-terminal region of TRKB which bound to BDNF, we set out to identify specific amino acid residues involved as points of contact between TRKB and BDNF. An EDAC-coupling reaction between BDNF and the truncated TRKB was performed, and the cross-linked complex was initially separated by Superdex 75 gel filtration (Fig. 7A) . These fractions were examined by SDS-PAGE (Fig. 7B) further by reversed phase HPLC using a Zorbax CN column as shown in Fig. 7C . The isolation of cross-linked peptides was performed by peptic digestion of HPLC fraction 3 followed by separation with reversed phase HPLC (Fig. 8) . Sequence analysis indicated that peptide P-1 contained four sequences (Table  IV) ; one sequence M-G-W-P-G-I-(D)-(D)-G-A-N-P-N (residues 348 -360) (peptide 1) derived from TRKB, whereas the other three sequences I-(R)-
, and S-V-X-D-S-I-S-E (residues 11-18) (peptide 4) were derived from BDNF. X denotes unidentified residues because of the presence of cysteine at these positions. Mass spectrometry of the intact peptide did not give a significant signal because of the disulfide-linked large peptide. After TCEP reduction a mass of 3,276 atomic mass units, corresponding to the sum of peptides 1 and 2, was detected, indicating the presence of a cross-link between peptides 1 and 2. However, the obtained mass was slightly higher (ϩ16) than the expected value (3,260 atomic mass units) probably because of oxidation of methionine. Sequence analysis showed that cycles 7 and 8 of peptide 1 gave a low yield of phenylthiohydantoin-Asp, suggesting that cross-linking reaction probably occurred at one of these residues. Direct analysis of the cross-linked peptide P-1 with the mass spectrometer did not show clearly that these three peptides were covalently linked together through both disulfide bonds and EDAC crosslinking. However, MALDI-mass spectrometry after TCEP reduction of the fragment P-1 showed that peptide 1 (TRKB) cross-linked peptide 2 (BDNF). For further confirmation, the cross-linked peptide P-1 was reduced and carboxymethylated to separate it from the other Cys-containing peptides. MALDImass spectrometry of the purified peptide revealed that the cross-linked peptide showed a mass of 3,382 atomic mass units, which is close to the expected mass of 3,376 atomic mass units.
DISCUSSION
Two Distinct Ligand Binding Domains-Using a combination of approaches, we report the identification of two neurotrophin binding domains in the TRKB receptor (Fig. 9) . These regions were first identified using correctly folded receptor and ligand to narrow the binding domains and to prevent the exclusion of regions dependent on three-dimensional structure for proper binding. The two domains correspond to the LRM-3 cysteine cluster-2 region and the vicinity of the second Ig-like domain, both independently bound immobilized BDNF. These regions were then examined in more detail using both wildtype and mutated synthetic peptides. Peptide affinity binding results indicated that smaller fragments of both domains could bind BDNF, whereas peptides corresponding to LRM-1 or LRM-2 did not show any specific binding to BDNF.
Previously it was reported that the LRM-2 region of TrkA specifically bound to nerve growth factor, whereas a similar region of TRKB could bind BDNF or NT-3 (11, 12) . Those studies did not detect neurotrophin binding to the Ig-like domain. However, both studies were done with unfolded proteins expressed in bacteria. Using refolded, mammalian expressed receptor mutants, Urfer et al. (18) reported significant binding of BDNF to the Ig-like domain of TRKB. Currently, it is unclear if these discrepancies resulted from the use of different techniques, species differences, or differences between the Trk receptors. However, it does appear that two general domains, the LRM and the second Ig-like domain, contribute to neurotrophin binding by the Trk receptors. Further comparative studies will be required to determine which differences in sequences between the Trk receptors are responsible for ligand binding and specificity.
Features of the TRKB Receptor Important for BDNF BindingThe K d values of the soluble and truncated forms of TRKB binding to BDNF were determined by surface plasmon resonance. The results indicate that the truncated TRKB receptor bound to BDNF, but the affinity was severalfold lower than for the soluble receptor. Several possible explanations may account for the observed difference. The truncated receptor lacks glycosylation and other regions of the extracellular domain, particularly three LRM regions, which may contribute to binding of BDNF or may serve to create an optimized conformation of the COOH-terminal region. It is difficult at present to compare these affinity measurements with other published reports (12, 15, 33) . There is some disagreement as to the actual K d for BDNF binding to cell surface-bound TRKB. Although several groups identified a receptor affinity for BDNF in the 1 nM range (12, 33) , only some groups have detected a higher affinity class in the 10 pM range (15) . An affinity measurement of the soluble receptor as determined by equilibrium sedimentation characterized the affinity (27) . However, all of these reports use different techniques for measuring K d , and thus a direct comparison between them is 
difficult. What can be concluded from this study is that the COOH-terminal region of the TRKB receptor contributes substantially to BDNF binding. Additional studies will be required to characterize other biological events that occur subsequent to binding. Previously, we reported that Chinese hamster ovary cell-derived TRKB protein contained 10 glycosylation sites, presumably located at the surface of the molecule (26) . These glycosylation sites are not likely to be involved in ligand-receptor interaction because of the structural restriction. Based on this assumption, since in the COOH-terminal BDNF binding domain of TRKB, the residue Asn 381 is glycosylated, the ligand binding Peptides K-1 and K-2 were derived from Lys-C digest of TRKB, identical to peptides AK-1 and AK-2. TF denotes the truncated form of TRKB which was expressed in E. coli cells. LRM-1-3 were chemically synthesized fragments. CC, cysteine cluster. region might be restricted to the region from residues 342-380. Two observations indicated that the disulfide-containing fragment AK-2 close to LRM-3 was involved in BDNF binding and that reduced/alkylated peptides of that fragment did not bind to BDNF-glass beads. These results suggest that proper peptide conformation in this region is required for much of BDNF binding. A similar observation has been reported for the interaction between thyrotropin-␤ and its receptor (34) . Unfortunately, the large number of cysteine residues in the NH 2 -terminal region of the receptor will complicate analysis of this domain. The data presented here further define important points of contact between the neurotrophins and TRKB receptor. Analysis of one of the binding domains (residues 342-394) identified specific amino acids involved in BDNF binding. Results derived from the use of mutant, synthetic peptides indicated that Asp 354 partly contributed to binding in this region as do amino acid residues Phe 347 and Tyr
361
. These observations imply that both ionic and hydrophobic forces are involved in the interaction between BDNF and TRKB.
Comparison with Other Immunoglobulin Domains-A variety of ligand binding sites in numerous receptors have been studied in many laboratories using different approaches. Deletion or domain analysis indicated that the Ig C2-like domain in several receptors plays an important role for ligand binding; these include keratinocyte growth factor receptor (35) , the macrophage colony-stimulating factor receptor (36) , and the intercellular adhesion molecule-1) (37). Our results indicate that similar to these other receptor-ligand interactions, the binding of BDNF to TRKB occurs in part to the second Ig-like domain (Fig. 9) . Interestingly, the COOH-terminal region (residues 342-394) between the second Ig-like domain and the membrane domain of the TRKB receptor does not contain any disulfide bond. Non-disulfide-linked Ig-like domains involved in ligand binding exist in several proteins, including Ig-like domain 4 of the stem cell factor receptor (38) , domain 3 of the CD4 molecule (39) , and domain 1 of the CD2 molecule (40) .
In conclusion, we describe the use of immobilized ligand or receptor to study interaction sites between a receptor and its ligand. This simple technique provides more direct results compared with site-directed mutagenesis and can use either folded or denatured proteins. The binding assay using synthetic peptide analogs described here was applied to the study of TRKBneurotrophin interactions and contributed to the identification of specific interaction sites. Further investigation of the points of contact between BDNF and TRKB may help in the development of small molecule compounds of potential utility in the treatment of a variety of neurological diseases.
